Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.42 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.42 |
| ▸ | ITGAV | P06756 | 1/20 | 0.42 |
| ▸ | ITGA5 | P08648 | 1/20 | 0.42 |
| ▸ | ITGA4 | P13612 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | CCR5 | P51681 | 2/20 | 0.39 |
| ▸ | AVPR2 | P30518 | 5/20 | 0.39 |
| ▸ | AVPR1A | P37288 | 5/20 | 0.39 |
| ▸ | RECQL | P46063 | 1/20 | 0.39 |
| ▸ | PAK1 | Q13153 | 1/20 | 0.39 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3622996 | 0.89 | HSD11B1 (0.45) | KMT2ATP53RAB9AALDH1A1PAK1 | |
| SCHEMBL3347661 | 0.89 | HSD11B1 (0.45) | KMT2ATP53RAB9AALDH1A1PAK1 | |
| SCHEMBL2586547 | 0.87 | CNR2 (0.43) | KMT2ATP53NPC1RAB9AHTT | |
| SCHEMBL9998804 | 0.87 | CNR2 (0.43) | KMT2ATP53NPC1RAB9AHTT | |
| SCHEMBL16727612 | 0.87 | CNR2 (0.43) | KMT2ATP53NPC1RAB9AHTT | |
| SCHEMBL18609854 | 0.87 | CNR2 (0.43) | KMT2ATP53NPC1RAB9AHTT | |
| SCHEMBL18790097 | 0.85 | CCR5 (0.40) | KMT2AMAPTALDH1A1LMNACCR5 | |
| SCHEMBL18532541 | 0.85 | CCR5 (0.40) | KMT2AMAPTALDH1A1LMNACCR5 | |
| SCHEMBL2586526 | 0.85 | CCR5 (0.40) | KMT2AMAPTALDH1A1LMNACCR5 | |
| SCHEMBL2579732 | 0.84 | CCR5 (0.39) | KMT2AMAPTALDH1A1LMNACCR5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230102258-A1 | C5AR ANTAGONISTS | CHEMOCENTRYX, INC. | 2023-03-30 | — | — | US | disclosed |
| EP-4015504-A1 | C5AR ANTAGONISTS | ChemoCentryx, Inc. (US) | 2022-06-22 | — | — | EP | disclosed |
| EP-3508477-B1 | C5AR ANTAGONISTS | CHEMOCENTRYX INC (US) | 2021-11-10 | — | — | EP | disclosed |
| US-10660897-B2 | C5aR antagonists | CHEMOCENTRYX, INC. (US) | 2020-05-26 | — | — | US | disclosed |
| EP-3078658-B1 | C5AR ANTAGONISTS | CHEMOCENTRYX INC (US) | 2019-04-10 | — | — | EP | disclosed |
| US-10035768-B2 | C5aR antagonists | CHEMOCENTRYX, INC. (US) | 2018-07-31 | — | — | US | disclosed |
| US-20180179160-A1 | C5AR ANTAGONISTS | CHEMOCENTRYX, INC. | 2018-06-28 | — | — | US | disclosed |
| EP-2585064-B1 | C5AR ANTAGONISTS | CHEMOCENTRYX INC (US) | 2017-05-03 | — | — | EP | disclosed |
| US-20170065604-A1 | C5aR ANTAGONISTS | CHEMOCENTRYX, INC. | 2017-03-09 | — | — | US | disclosed |
| US-9573897-B2 | C5AR antagonists | CHEMOCENTRYX, INC. (US) | 2017-02-21 | — | — | US | disclosed |
| US-20160229802-A1 | C5AR ANTAGONISTS | CHEMOCENTRYX, INC. | 2016-08-11 | — | — | US | disclosed |
| EP-2381778-B1 | C5AR ANTAGONISTS | CHEMOCENTRYX INC (US) | 2016-06-08 | — | — | EP | disclosed |
| US-9126939-B2 | C5AR antagonists | CHEMOCENTRYX, INC. | 2015-09-08 | — | — | US | disclosed |
| US-20150141425-A1 | C5aR ANTAGONISTS | CHEMOCENTRYX, INC. | 2015-05-21 | — | — | US | disclosed |
| US-8906938-B2 | C5aR antagonists | CHEMOCENTRYX, INC. (US) | 2014-12-09 | — | — | US | disclosed |
| US-20130317028-A1 | C5aR ANTAGONISTS | CHEMOCENTRYX, INC. (US) | 2013-11-28 | — | — | US | disclosed |
| US-20130172347-A1 | C5AR ANTAGONISTS | CHEMOCENTRYX, INC. | 2013-07-04 | — | — | US | disclosed |
| US-8445515-B2 | C5aR antagonists | CHEMOCENTRYX, INC. (US) | 2013-05-21 | — | — | US | disclosed |
| US-20100311753-A1 | C5aR ANTAGONISTS | CHEMOCENTRYX, INC. (US) | 2010-12-09 | — | — | US | disclosed |
| US-20100160320-A1 | C5aR ANTAGONISTS | CHEMOCENTRYX, INC. (US) | 2010-06-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100160320-A1 | C5aR ANTAGONISTS | C5AR1, C5AR2, C3AR1 | KMT2A 4442/4885TP53 3390/4885NPC1 2134/4885 |
| US-20150141425-A1 | C5aR ANTAGONISTS | C5AR1, C5AR2, C3AR1 | KMT2A 4442/4885TP53 3390/4885NPC1 2134/4885 |
| US-10660897-B2 | C5aR antagonists | C5AR1, C5AR2, C3AR1 | KMT2A 4442/4885TP53 3390/4885NPC1 2134/4885 |
| US-20160229802-A1 | C5AR ANTAGONISTS | C5AR1, C5AR2, C3AR1 | KMT2A 4442/4885TP53 3390/4885NPC1 2134/4885 |
| US-20180179160-A1 | C5AR ANTAGONISTS | C5AR1, C5AR2, C3AR1 | KMT2A 4442/4885TP53 3390/4885NPC1 2134/4885 |
| US-10035768-B2 | C5aR antagonists | C5AR1, C5AR2, C3AR1 | KMT2A 4442/4885TP53 3390/4885NPC1 2134/4885 |
| US-20130317028-A1 | C5aR ANTAGONISTS | C5AR1, C5AR2, C3AR1 | KMT2A 4442/4885TP53 3390/4885NPC1 2134/4885 |
| US-20230102258-A1 | C5AR ANTAGONISTS | C5AR1, C5AR2, C3AR1 | KMT2A 4442/4885TP53 3390/4885NPC1 2134/4885 |
| US-20100311753-A1 | C5aR ANTAGONISTS | C5AR1, C5AR2, C3AR1 | KMT2A 4442/4885TP53 3390/4885NPC1 2134/4885 |
| US-20130172347-A1 | C5AR ANTAGONISTS | C5AR1, C5AR2, C3AR1 | KMT2A 4442/4885TP53 3390/4885NPC1 2134/4885 |
| US-20170065604-A1 | C5aR ANTAGONISTS | C5AR1, C5AR2, C3AR1 | KMT2A 4510/4885TP53 3892/4885NPC1 2536/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.